Follicular lymphoma dynamics.

Cell of origin (COO) Committed precursor cell (CPC) Follicular lymphoma (FL) Plasticity Single-cell RNA-seq Tumor microenvironment Unmet medical need

Journal

Advances in immunology
ISSN: 1557-8445
Titre abrégé: Adv Immunol
Pays: United States
ID NLM: 0370425

Informations de publication

Date de publication:
2021
Historique:
entrez: 28 6 2021
pubmed: 29 6 2021
medline: 26 10 2021
Statut: ppublish

Résumé

Follicular lymphoma (FL) is an indolent yet challenging disease. Despite a generally favorable response to immunochemotherapy regimens, a fraction of patients does not respond or relapses early with unfavorable prognosis. For the vast majority of those who initially respond, relapses will repeatedly occur with increasing refractoriness to available treatments. Addressing the clinical challenges in FL warrants deep understanding of the nature of treatment-resistant FL cells seeding relapses, and of the biological basis of early disease progression. Great progress has been made in the last decade in the description and interrogation of the (epi)genomic landscape of FL cells, of their major dependency to the tumor microenvironment (TME), and of the stepwise lymphomagenesis process, from healthy to subclinical disease and to overt FL. A new picture is emerging, in which an ever-evolving tumor-TME duo sparks a complex and multilayered clonal and functional heterogeneity, blurring the discovery of prognostic biomarkers, patient stratification and reliable designs of risk-adapted treatments. Novel technological approaches allowing to decipher both tumor and TME heterogeneity at the single-cell level are beginning to unravel unsuspected cell dynamics and plasticity of FL cells. The upcoming drawing of a comprehensive functional picture of FL within its ecosystem holds great promise to address the unmet medical needs of this complex lymphoma.

Identifiants

pubmed: 34176559
pii: S0065-2776(21)00016-X
doi: 10.1016/bs.ai.2021.05.002
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-103

Subventions

Organisme : NCI NIH HHS
ID : R01 CA172492
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA260176
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Pierre Milpied (P)

Aix Marseille University, CNRS, INSERM, CIML, Marseille, France.

Anita K Gandhi (AK)

Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States.

Guillaume Cartron (G)

Department of Hematology, Centre Hospitalier Universitaire Montpellier, UMR-CNRS 5535, Montpellier, France.

Laura Pasqualucci (L)

Pathology and Cell Biology, Institute for Cancer Genetics, Columbia University, New York City, NY, United States.

Karin Tarte (K)

INSERM U1236, Univ Rennes, EFS Bretagne, CHU Rennes, Rennes, France.

Bertrand Nadel (B)

Aix Marseille University, CNRS, INSERM, CIML, Marseille, France. Electronic address: nadel@ciml.univ-mrs.fr.

Sandrine Roulland (S)

Aix Marseille University, CNRS, INSERM, CIML, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH